The trial contributed to understanding sotagliflozin’s 20:1 SGLT2:SGLT1 receptor affinity and its implications for cardiovascular risk reduction in patients with diabetes and kidney disease (23). This evidence concerns the gene SLC5A2 and kidney disorder.